ClinicalTrials.gg
CompletedNCT03502616Updated Sep 17, 2021Results posted

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

A Phase 3 interventional study of Tofacitinib in Ankylosing Spondylitis, sponsored by Pfizer. Completed at 99 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Spondylitis, Ankylosing by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Spondylitis, Ankylosing · Pfizer.

Enrollment
5th of 18
270 · median 129
Started
2018
the only one that year
Phase 3
7 of 34
none open now
Registered
32nd of 34
by date

Among the 34 studies in Spondylitis, Ankylosing by Pfizer, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 3, and was the 32nd registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

1 of the 34 studies in Spondylitis, Ankylosing by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Spondylitis, Ankylosing by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria for AS (1984).
  • Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.
  • Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or intolerant to NSAIDs.

Exclusion criteria

Exclusion Criteria:

  • History of known or suspected complete ankylosis of the spine.
  • History of allergies, intolerance or to lactose or tofacitinib.
  • History of any other rheumatic disease.
  • Any subject with condition affecting oral drug absorption.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    Tofacitinib

    Drug: Tofacitinib

  • Placebo comparator
    Placebo

    Drug: Tofacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16

    ASAS20 assess 4 domains: Patient Global Assessment of Disease (PGA) (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Question \[Q\]5 and Q6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: greater than or equal to (\>=) 20 percent (%) improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Ankylosing Spondylitis (ASAS)40 Response at Week 16

    ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.

    Time frame: Week 16

  2. Number of Participants With Treatment Emergent Adverse Events (AEs)

    An AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Treatment-emergent were events between first dose of study drug and up to 48 weeks that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to Week 16 and Baseline up to Week 48

  3. Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity

    AE: any untoward medical occurrence in subject who receive study drug without regard to possibility of causal relationship. Treatment-emergent AEs were events that occurred between first dose of study drug and up to 48 weeks that were absent before treatment or that worsened relative to pretreatment state. The severity grades (mild, moderate and severe) were defined as - mild: did not interfere with participant's usual function, moderate: Interfered to some extent with participant's usual function and severe: Interfered significantly with participant's usual function.

    Time frame: Baseline up to Week 16 and Baseline up to Week 48

  4. Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

    Hematology (Hemoglobin, Hematocrit, Erythrocyte, Lymphocyte/Leukocyte, Neutrophil/Leukocyte \<0.8\*Lower limit of normal (LLN), Reticulocyte \>1.5\*Upper limit of normal (ULN), Erythrocyte Mean Corpuscular Volume, Erythrocyte Mean Corpuscular Hemoglobin, Erythrocyte Mean Corpuscular HGB Concentration \<0.9\*LLN, \>1.1\*ULN, Reticulocyte/Erythrocyte, Leukocyte \>1.5\*ULN, Lymphocyte, Neutrophil \<0.8\*LLN and \>1.2\*ULN, Basophil, Basophil/Leukocyte, Eosinophil, Eosinophil/Leukocyte, Monocyte, Monocyte/Leukocyte \>1.2\*ULN); Clinical Chemistry (Bilirubin, Glucose \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase \>3.0\*ULN, Urea, Creatinine, Triglyceride, Cholesterol \>1.3\*ULN, LDL Cholesterol\>1.2\*ULN, Potassium, C Reactive Protein \>1.1\*ULN, Bicarbonate \<0.9\*LLN, Creatine Kinase \>2.0\*ULN, HDL Cholesterol \<0.8\*LLN), Urinalysis (Specific Gravity \>1.035, pH \>8, Glucose, Ketones, Protein, Hemoglobin \>=1, Erythrocyte, Leukocyte \>=20, Granular Cast, Hyaline Cast\>1.

    Time frame: Baseline up to Week 16 and Baseline up to Week 48

  5. Number of Participants With Vital Signs Abnormalities

    Criteria for abnormalities in vital signs: Pulse rate \<40 beats per minute (bpm) to \>120 bpm, Sitting Diastolic blood pressure \< 50 millimeter of mercury (mmHg), increase and decrease in change from baseline of \>= 20mmHg, sitting systolic blood pressure \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg.

    Time frame: Baseline up to Week 16 and Baseline up to Week 48

  6. Number of Participants With Abnormalities in Physical Examination

    Complete physical examination: included general appearance, skin (presence of rash), heent (head, eyes, ears, nose and throat), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs), lower extremities (presence of peripheral edema), abdominal (palpation and auscultation), neurologic (mental status, station, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Abnormalities in physical examination was based on investigator's discretion/clinical judgement.

    Time frame: Screening, Week 16, and Week 48

  7. Number of Participants With Electrocardiogram (ECG) Abnormalities

    Twelve-lead electrocardiograms (ECGs) were obtained for all participants. Criteria for ECG abnormality: PR interval \>=300 and a percent change from baseline of \>=25 or 50%; QRS duration \>=140 and a percent change from baseline of \>=50%; QT interval \>=500; QTCB, QTCF interval \<480 or \>=450, \<500 or \>=480, \>=500, change from baseline of \<60 and \>=30, and change from baseline of \>=60.

    Time frame: Baseline up to Week 16, Baseline up to Week 48

  8. Percentage of Participants Achieving ASAS20 Response at Weeks 2, 4, 8, 12, 24, 32, 40 and 48

    ASAS20 assess 4 domains: PGA of Disease (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (BASFI; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: \>= 20% improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.

    Time frame: Weeks 2, 4, 8, 12, 24, 32, 40 and 48

  9. Percentage of Participants Achieving ASAS40 Response at Weeks 2, 4, 8, 12, 24, 32, 40 and 48

    ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.

    Time frame: Weeks 2, 4, 8, 12, 24, 32, 40 and 48

  10. Change From Baseline in Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and calculated by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(high sensitivity \[hs\] CRP mg/Liter \[L\] + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  11. Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    Blood samples were collected for analysis of hsCRP using an assay analyzed by central laboratory. hsCRP is an acute phase reactant, which was indicative of inflammation and of its severity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  12. Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Weeks 16 and 48

    The ASQoL was an 18-item questionnaire assessed the amount of restriction participant experienced in daily activities, level of pain and fatigue, and the impact on the participant's emotional state. Each item was scored as 0 (no impact) or 1 (yes - impact). A total score was calculated by summing the items. The total score ranged from 0 (no impact) to 18 (yes-impact), with higher values indicated more impaired health-related quality of life.

    Time frame: Baseline, Weeks 16 and 48

  13. Change From Baseline in Short-Form-36 Health Survey-Version 2 Acute (SF-36v2) Score at Weeks 16 and 48

    SF-36 v.2 (Acute): 36-item generic health status measure. It measured 8 general health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, mental health. These domains were aggregated into 2 summary scores - physical component summary (PCS), mental component summary (MCS). Four domains comprised PCS score (physical functioning, role-physical, bodily pain, general health) and remaining 4 domains comprised MCS score (vitality, social functioning, role-emotional, mental health). Normalized domain scores, PCS, MCS scores are used in analyses. Component and domain scores were scored by using United States 1998 general population norm. Resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scale and component summary measures had means of 50 and standard deviations of 10. Higher PCS/MCS/domain score represent better health status.

    Time frame: Baseline, Weeks 16 and 48

  14. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Cervical Rotation Angle at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    BASMI assess axial status and spinal mobility. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component score mapped between 0 and 10, high score=more impairment of axial status, spinal mobility. For cervical rotation angle, participant sit straight on chair with chin level and hands on knees. Blinded assessor place goniometer at top of head in line with nose and ask participant to rotate neck maximally to left, follows with goniometer and record angle between sagittal plane and new plane after rotation. A second reading obtained and both readings recorded. Procedure repeated for right side. Better of two for each side was selected for scoring. Scoring done by calculating mean of left and right measurement and recorded in degrees (range: 0 to 90), higher cervical rotation value=better health status.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  15. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Intermalleolar Distance at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    BASMI assessed axial status and spinal mobility, using linear function. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of intermalleolar distances, participant should lie supine with the knees straight and feet/toes pointing straight up and asked to separate the legs as far as possible and the distance between the medial malleoli was measured (in Centimeters \[cm\] to the nearest 0.1 cm). Distance (in cm) was greater than or equal to 0, with no maximum defined range: higher intermalleolar distance value indicates better health status.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  16. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Lateral Spinal Flexion at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    BASMI assess axial status, spinal mobility, using linear function. It composed of 5 clinical measures. BASMI - Linear Method score-average of 5 component scores mapped between 0 and 10, with high scores =more impairment of axial status, spinal mobility. For assessment of lateral spinal flexion: participant stand upright with head and back rest against wall as close as possible with shoulders level and feet 30 cm apart and feet parallel. At tip of middle finger, place a mark on thigh. This neutral position recorded. Participant bend sideways without bending knees or lifting heels while attempting to keep shoulders in same position (flexion position). Second mark placed, lateral flexion recorded (left or right as appropriate) using cm tape measure. Two tries for left, two tries for right measured. Result of two tries recorded for left and right separately in cm to nearest 0.1 cm. Distance (in cm) should be \>=0, with no maximum defined range: high value indicates better health status.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  17. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Lumbar Flexion (Modified Schober) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    BASMI assessed axial status and spinal mobility. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of lumbar flexion, With the participant standing erect and outer edges of feet 30 cm apart, a mark was placed in the midpoint of a line that joins the posterior superior iliac spines (baseline mark). A second mark (A) was placed 10 cm above the baseline mark and a third mark (B) 5 cm below the baseline mark. Then have the participant maximally bend forward, keeping the knees fully extended. With the participant's spine in full flexion, the distance between marks A and B (in cm to the nearest 0.1 cm) was re-measured. Distance (in cm) was greater than or equal to 0, with no maximum defined range. Higher value indicates better health status.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  18. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Tragus-to-wall Distance at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    BASMI assessed axial status and spinal mobility, using linear function. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of tragus-to-wall distance, participant was placed standing with his/her back against the wall; knees straight; scapulae, buttocks, and heels against wall; and head in as neutral position as possible. The distance between the tragus and wall in cm was measured (to the nearest 0.1 cm) from both the right side and left side at the maximum effort to touch the head against the wall. Distance should be greater than or equal to 0 cm with no defined maximum value, lower tragus-to-wall value indicates better health status.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  19. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Linear Method Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    The BASMI was used to assess the axial status and spinal mobility (cervical, dorsal and lumbar spine, hips and pelvic soft tissue) and was analyzed using the linear function method. BASMI score composed of five clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, and cervical rotation. BASMI - Linear Method score was the average of 5 individual component scores mapped between 0 and 10 and thus the BASMI - Linear Method total score ranged from 0 (very good) to 10 (very poor), wherein higher scores indicated more impairment of axial status and spinal mobility; lower scores indicated better health status.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  20. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    FACIT-F is a 13-item questionnaire (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired), with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three type of scores were derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score was calculated by summing the 13 items (range 0 \[not at all\] to 52 \[very much\]); higher scores represent less fatigue status. In this outcome measure, change from baseline in FACIT-F total score was reported.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  21. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    FACIT-F is a 13-item (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired) questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-F experience domain score was calculated by summing 5 items: I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy. FACIT-F total experience domain score ranged from 0 (not at all) to 20 (very much), with higher scores represented better (less) fatigue impact on daily functioning. In this outcome measure, change from baseline in FACIT-F experience domain score was reported.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  22. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    FACIT-F is a 13-item (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired) questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-F experience domain score calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless, I feel tired, and I have energy, while FACIT-F impact domain score was calculated by summing the remaining 8 items. FACIT-F impact domain score ranged from 0 (not at all) to 32 (very much), with higher scores represented better (less) fatigue impact on daily functioning. In this outcome measure, change from baseline in FACIT-F impact domain score was reported.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  23. Change From Baseline in Patient's Global Assessment of Disease (PGA) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    Participants answered the question, "How active was your spondylitis on average during the last week?. Participant's response was recorded using a numerical rating scale ranged from 0 (Not Active) to 10 (Very Active), with higher scores indicated more severe disease.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  24. Change From Baseline in Patient's Assessment of Spinal Pain: Total Back Pain at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    Participants marked their level of total back pain on a numerical rating scale (NRS) ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  25. Change From Baseline in Patient's Assessment of Spinal Pain: Nocturnal Spinal Pain at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    Participants marked their level of nocturnal spinal pain on a NRS ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  26. Change From Baseline in in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    BASFI was a functional index which included 10 items assessing ability of participants to perform normal daily activities. The first 8 questions/items consider activities related to functional anatomy. The final 2 questions/items assess the participants' ability to cope with everyday life. Each item was scored on a scale of 0=easy to 10=impossible. The BASFI total score was calculated as the average score of these 10 individual items. BASFI total score ranged from 0 (easy) to 10 (impossible), where higher scores indicated more severe disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  27. Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Inflammation (Morning Stiffness) Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    The BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity. BASDAI inflammation score was derived by taking mean of the responses of question 5 and 6 and ranged from 0 (none) to 10 (very severe), where higher score indicated more inflammation (morning stiffness).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  28. Percentage of Participants Achieving ASAS 5/6 Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    ASAS 5/6 consists of 6 domains: 4 used in ASAS20 - PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), Spinal Pain (total back pain) (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), CRP (was measured in mg per liter) and Spinal mobility was measured in centimeter and calculated as mean of right and left measurements of lateral spinal flexion from BASMI. ASAS 5/6: defined as \>=20% improvement in at least 5 domains.

    Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  29. Percentage of Participants Achieving ASAS Partial Remission at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    Partial remission was defined as a score of 2 or less (on a scale of 0-10, where 0=no disease activity and 10=high disease activity) in each of the 4 domains in ASAS. These 4 domains included: PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity).

    Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  30. Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    The BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  31. Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. BASDAI score was calculated by computing mean of questions 5 and 6 and adding it to sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity. BASDAI50 response was defined as decrease of \>=50% from Baseline in BASDAI score at specified time points. Percentage of participants with BASDAI 50 response at specified weeks are reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  32. Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Clinically Important Improvement Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) clinically important improvement was defined as decrease from Baseline of \>=1.1 units in ASDAS(CRP) score.

    Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  33. Percentage of Participants Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Major Improvement Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) major improvement was defined as a response if improvement (decrease) from Baseline in ASDAS(CRP) of \>=2.0 units.

    Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  34. Percentage of Participants Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Inactive Disease Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) inactive disease is defined as a response if actual ASDAS(CRP) was \<1.3 units.

    Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  35. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Weeks 4, 8, 12, 16, 24, 32, 40 and 48

    The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Sites assessed included 1st costochondral joint (left \[l\]/right \[r\]), 7th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. Each site was graded for the presence (1) and absence (0) of tenderness yielding total MASES score ranging from 0 (no tenderness) to 13 (worst possible score) with higher score indicated more severe tenderness.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 24, 32, 40 and 48

  36. Change From Baseline in Swollen Joint Count (SJC) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    Swollen joint count was an assessment on 44 joints (sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals, thumb interphalangeal, proximal interphalangeals, knees, ankles, and metatarsophalangeals). Each joint was assessed for swelling as: Present or Absent. Artificial joints were not assessed

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  37. Change From Baseline in Spinal Mobility (Chest Expansion ) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

    Chest expansion (measured in centimeters (cm), is defined as the difference in the thoracic circumference during full expiration versus full inspiration. This was measured at the 4th intercostal space. The difference between maximal inspiration and expiration of the two attempts was recorded. The better of the two attempts was used to calculate chest expansion which was defined to be greater than or equal to 0 cm with no defined maximum/upper limit. Greater chest circumference corresponds to higher score indicated more spinal mobility/better health status (measured as Chest Expansion in cm).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

  38. Change From Baseline in EuroQol 5 Dimensions 3 Levels (EQ-5D-3L) Score at Weeks 16 and 48

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions. Participants rated 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The mean of the summed score ranged from 1 to 3 with "1" corresponding to no problems and "3" corresponding to severe problems in the 5 dimensions, where higher score indicates more severe problems.

    Time frame: Baseline, Weeks 16 and 48

  39. Change From Baseline in EuroQol Visual Analogue Scale (EQ-VAS) Score (mm) at Weeks 16 and 48

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions. Its second part included EQ-VAS. EQ-VAS recorded the participant's self-rated health on a VAS ranging from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state), with higher scores indicating better health state.

    Time frame: Baseline, Weeks 16 and 48

  40. Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to Health Problem at Weeks 16 and 48

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent work time missed due to health problem was a subscale and calculated as: Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity.

    Time frame: Baseline, Weeks 16 and 48

  41. Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working Due to Health Problem at Weeks 16 and 48

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent Impairment while Working due to Health Problem was a subscale and calculated as: Q5/10 for those who were currently employed and actually worked in the past 7 days. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity.

    Time frame: Baseline, Weeks 16 and 48

  42. Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment Due to Health Problem at Weeks 16 and 48

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent overall work impairment due to health problem was a subscale and calculated as: Q2/(Q2+Q4)+\[(1- Q2/(Q2+Q4))×(Q5/10)\] for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment.

    Time frame: Baseline, Weeks 16 and 48

  43. Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment Due to Health Problem at Weeks 16 and 48

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent activity impairment due to health problem was a subscale and calculated as: Q6/10 for all respondents. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment.

    Time frame: Baseline, Weeks 16 and 48

07

Results

Posted Jan 11, 2021

Participant flow

Up to Week 16
Participant flow — Up to Week 16
MilestoneTofacitinibPlacebo Then Tofacitinib
Started134136
Treated133136
Completed132133
Not completed23
Withdrew: Withdrawal by subject12
Withdrew: Lost to follow-up01
Withdrew: Randomized, but not treated10
Week 16 to Week 48
Participant flow — Week 16 to Week 48
MilestoneTofacitinibPlacebo Then Tofacitinib
Started132133
Treated132133
Completed125127
Not completed76
Withdrew: Withdrawal by subject66
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16

ASAS20 assess 4 domains: Patient Global Assessment of Disease (PGA) (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Question \[Q\]5 and Q6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: greater than or equal to (\>=) 20 percent (%) improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 1656.3929.41
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 27.08 · 95% CI 15.89 to 38.28
SecondaryPercentage of Participants Achieving Ankylosing Spondylitis (ASAS)40 Response at Week 16

ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Ankylosing Spondylitis (ASAS)40 Response at Week 16
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Percentage of Participants Achieving Ankylosing Spondylitis (ASAS)40 Response at Week 1640.6012.50
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 28.17 · 95% CI 18.26 to 38.09
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

An AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Treatment-emergent were events between first dose of study drug and up to 48 weeks that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to Week 16 and Baseline up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
ParticipantsTofacitinibPlacebo Then Tofacitinib
Up to Week 167370
Up to Week 4810393
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) by Severity

AE: any untoward medical occurrence in subject who receive study drug without regard to possibility of causal relationship. Treatment-emergent AEs were events that occurred between first dose of study drug and up to 48 weeks that were absent before treatment or that worsened relative to pretreatment state. The severity grades (mild, moderate and severe) were defined as - mild: did not interfere with participant's usual function, moderate: Interfered to some extent with participant's usual function and severe: Interfered significantly with participant's usual function.

Time frame:
Baseline up to Week 16 and Baseline up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
ParticipantsTofacitinibPlacebo Then Tofacitinib
Up to Week 16: Mild5352
Up to Week 16: Moderate1818
Up to Week 16: Severe20
Up to Week 48: Mild5757
Up to Week 48: Moderate4036
Up to Week 48: Severe60
SecondaryNumber of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

Hematology (Hemoglobin, Hematocrit, Erythrocyte, Lymphocyte/Leukocyte, Neutrophil/Leukocyte \<0.8\*Lower limit of normal (LLN), Reticulocyte \>1.5\*Upper limit of normal (ULN), Erythrocyte Mean Corpuscular Volume, Erythrocyte Mean Corpuscular Hemoglobin, Erythrocyte Mean Corpuscular HGB Concentration \<0.9\*LLN, \>1.1\*ULN, Reticulocyte/Erythrocyte, Leukocyte \>1.5\*ULN, Lymphocyte, Neutrophil \<0.8\*LLN and \>1.2\*ULN, Basophil, Basophil/Leukocyte, Eosinophil, Eosinophil/Leukocyte, Monocyte, Monocyte/Leukocyte \>1.2\*ULN); Clinical Chemistry (Bilirubin, Glucose \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase \>3.0\*ULN, Urea, Creatinine, Triglyceride, Cholesterol \>1.3\*ULN, LDL Cholesterol\>1.2\*ULN, Potassium, C Reactive Protein \>1.1\*ULN, Bicarbonate \<0.9\*LLN, Creatine Kinase \>2.0\*ULN, HDL Cholesterol \<0.8\*LLN), Urinalysis (Specific Gravity \>1.035, pH \>8, Glucose, Ketones, Protein, Hemoglobin \>=1, Erythrocyte, Leukocyte \>=20, Granular Cast, Hyaline Cast\>1.

Time frame:
Baseline up to Week 16 and Baseline up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsTofacitinibPlacebo Then Tofacitinib
Up to Week 16106129
Up to Week 48126131
SecondaryNumber of Participants With Vital Signs Abnormalities

Criteria for abnormalities in vital signs: Pulse rate \<40 beats per minute (bpm) to \>120 bpm, Sitting Diastolic blood pressure \< 50 millimeter of mercury (mmHg), increase and decrease in change from baseline of \>= 20mmHg, sitting systolic blood pressure \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg.

Time frame:
Baseline up to Week 16 and Baseline up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Abnormalities
ParticipantsTofacitinibPlacebo Then Tofacitinib
Up to Week 16, Pulse rate: <40 bpm00
Up to Week 16, Pulse rate: >120 bpm00
Up to Week 16, Sitting diastolic blood pressure: <50 mmHg00
Up to Week 16, Sitting diastolic blood pressure: Change >= 20mmHg increase24
Up to Week 16, Sitting diastolic blood pressure: Change >= 20mmHg decrease64
Up to Week 16, Sitting systolic blood pressure: <90mmHg10
Up to Week 16, Sitting systolic blood pressure: Change >= 30mmHg increase24
Up to Week 16, Sitting systolic blood pressure: Change >= 30mmHg decrease25
Up to Week 48, Pulse rate: <40 bpm00
Up to Week 48, Pulse rate: >120 bpm01
Up to Week 48, Sitting diastolic blood pressure: <50 mmHg00
Up to Week 48, Sitting diastolic blood pressure: Change >= 20mmHg increase58
Up to Week 48, Sitting diastolic blood pressure: Change >= 20mmHg decrease118
Up to Week 48, Sitting systolic blood pressure: <90mmHg10
Up to Week 48, Sitting systolic blood pressure: Change >= 30mmHg increase55
Up to Week 48, Sitting systolic blood pressure: Change >= 30mmHg decrease57
SecondaryNumber of Participants With Abnormalities in Physical Examination

Complete physical examination: included general appearance, skin (presence of rash), heent (head, eyes, ears, nose and throat), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs), lower extremities (presence of peripheral edema), abdominal (palpation and auscultation), neurologic (mental status, station, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Abnormalities in physical examination was based on investigator's discretion/clinical judgement.

Time frame:
Screening, Week 16, and Week 48
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Physical Examination
ParticipantsTofacitinibPlacebo Then Tofacitinib
Abdomen: Screening21
Abdomen: Week 1612
Abdomen: Week 4811
Extremities: Screening1715
Extremities: Week 16814
Extremities: Week 4847
General appearance: Screening1011
General appearance: Week 1699
General appearance: Week 4876
Head, eyes, ears, nose, throat: Screening57
Head, eyes, ears, nose, throat: Week 1647
Head, eyes, ears, nose, throat: Week 4837
Heart: Screening22
Heart: Week 1602
Heart: Week 4802
Lungs: Screening10
Lungs: Week 1600
Lungs: Week 4800
Lymph nodes: Screening23
Lymph nodes: Week 1612
Lymph nodes: Week 4812
Neurological: Screening40
Neurological: Week 1610
Neurological: Week 4820
Skin: Screening1818
Skin: Week 161413
Skin: Week 481212
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

Twelve-lead electrocardiograms (ECGs) were obtained for all participants. Criteria for ECG abnormality: PR interval \>=300 and a percent change from baseline of \>=25 or 50%; QRS duration \>=140 and a percent change from baseline of \>=50%; QT interval \>=500; QTCB, QTCF interval \<480 or \>=450, \<500 or \>=480, \>=500, change from baseline of \<60 and \>=30, and change from baseline of \>=60.

Time frame:
Baseline up to Week 16, Baseline up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsTofacitinibPlacebo Then Tofacitinib
Up to Week 16, PR interval: >=30000
Up to Week 16, PR interval: %Change>=25/50%01
Up to Week 16, QRS duration: >=14011
Up to Week 16, QRS duration: %Change>=50%00
Up to Week 16, QT interval: >=50000
Up to Week 16, QTCB interval: >=450 and <48037
Up to Week 16, QTCB interval: >=480 and <50001
Up to Week 16, QTCB interval: >=50000
Up to Week 16, QTCB interval: change >=30 and <6097
Up to Week 16, QTCB interval: change >=6000
Up to Week 16, QTCF interval: >=450 and <48034
Up to Week 16, QTCF interval: >=480 and <50000
Up to Week 16, QTCF interval: >=50000
Up to Week 16, QTCF interval: change >=30 and <6053
Up to Week 16, QTCF interval: change >=6000
Up to Week 48, PR interval: >=30000
Up to Week 48, PR interval: %Change>=25/50%01
Up to Week 48, QRS duration: >=14031
Up to Week 48, QRS duration: %Change>=50%00
Up to Week 48, QT interval: >=50001
Up to Week 48, QTCB interval: >=450 and <4801010
Up to Week 48, QTCB interval: >=480 and <50011
Up to Week 48, QTCB interval: >=50000
Up to Week 48, QTCB interval: change >=30 and <601411
Up to Week 48, QTCB interval: change >=6010
Up to Week 48, QTCF interval: >=450 and <48055
Up to Week 48, QTCF interval: >=480 and <50010
Up to Week 48, QTCF interval: >=50000
Up to Week 48, QTCF interval: change >=30 and <6097
Up to Week 48, QTCF interval: change >=6010
SecondaryPercentage of Participants Achieving ASAS20 Response at Weeks 2, 4, 8, 12, 24, 32, 40 and 48

ASAS20 assess 4 domains: PGA of Disease (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (BASFI; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: \>= 20% improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.

Time frame:
Weeks 2, 4, 8, 12, 24, 32, 40 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS20 Response at Weeks 2, 4, 8, 12, 24, 32, 40 and 48
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Week 228.5710.29
Week 451.1319.85
Week 857.1425.00
Week 1263.9129.41
Week 2463.1659.56
Week 3268.4264.71
Week 4068.4266.91
Week 4865.4160.29
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0001 · Difference in percentage: 18.28 · 95% CI 9.06 to 27.50
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 31.35 · 95% CI 20.64 to 42.06
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 32.24 · 95% CI 21.32 to 43.17
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 34.61 · 95% CI 23.63 to 45.58
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.5360 · Difference in percentage: 3.65 · 95% CI -7.92 to 15.22
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.4971 · Difference in percentage: 3.83 · 95% CI -7.22 to 14.87
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.7792 · Difference in percentage: 1.58 · 95% CI -9.49 to 12.66
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.3685 · Difference in percentage: 5.22 · 95% CI -6.15 to 16.58
SecondaryPercentage of Participants Achieving ASAS40 Response at Weeks 2, 4, 8, 12, 24, 32, 40 and 48

ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.

Time frame:
Weeks 2, 4, 8, 12, 24, 32, 40 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS40 Response at Weeks 2, 4, 8, 12, 24, 32, 40 and 48
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Week 210.534.41
Week 427.073.68
Week 834.595.88
Week 1242.8611.76
Week 2448.1241.91
Week 3250.3844.12
Week 4050.3842.65
Week 4850.3844.85
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0548 · Difference in percentage: 6.12 · 95% CI -0.13 to 12.37
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 23.43 · 95% CI 15.30 to 31.56
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 28.56 · 95% CI 19.66 to 37.47
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 31.18 · 95% CI 21.34 to 41.02
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.2926 · Difference in percentage: 6.29 · 95% CI -5.43 to 18.01
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.2856 · Difference in percentage: 6.37 · 95% CI -5.32 to 18.06
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.1894 · Difference in percentage: 7.83 · 95% CI -3.87 to 19.54
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.3544 · Difference in percentage: 5.59 · 95% CI -6.24 to 17.43
SecondaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and calculated by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(high sensitivity \[hs\] CRP mg/Liter \[L\] + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 2-0.88 ± 0.056-0.17 ± 0.056
Week 4-1.14 ± 0.065-0.24 ± 0.065
Week 8-1.30 ± 0.074-0.24 ± 0.074
Week 12-1.38 ± 0.075-0.28 ± 0.075
Week 16-1.36 ± 0.073-0.39 ± 0.073
Week 24-1.51 ± 0.082-1.32 ± 0.081
Week 32-1.56 ± 0.084-1.37 ± 0.084
Week 40-1.65 ± 0.086-1.40 ± 0.086
week 48-1.70 ± 0.087-1.50 ± 0.086
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.71 · 95% CI -0.85 to -0.57
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.90 · 95% CI -1.07 to -0.74
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.06 · 95% CI -1.25 to -0.87
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.09 · 95% CI -1.28 to -0.90
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.98 · 95% CI -1.16 to -0.79
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0623 · Ls mean difference: -0.19 · 95% CI -0.40 to 0.01
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0836 · Ls mean difference: -0.18 · 95% CI -0.39 to 0.02
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0205 · Ls mean difference: -0.25 · 95% CI -0.47 to -0.04
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0614 · Ls mean difference: -0.20 · 95% CI -0.42 to 0.01
SecondaryChange From Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

Blood samples were collected for analysis of hsCRP using an assay analyzed by central laboratory. hsCRP is an acute phase reactant, which was indicative of inflammation and of its severity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Milligrams per deciliter (mg/dL)
Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Milligrams per deciliter (mg/dL)TofacitinibPlacebo Then Tofacitinib
Week 2-1.07 ± 0.089-0.14 ± 0.088
Week 4-1.06 ± 0.094-0.14 ± 0.094
Week 8-1.05 ± 0.153-0.03 ± 0.152
Week 12-1.11 ± 0.089-0.15 ± 0.090
Week 16-1.05 ± 0.096-0.09 ± 0.096
Week 24-1.21 ± 0.058-1.16 ± 0.058
Week 32-1.16 ± 0.076-1.08 ± 0.075
Week 40-1.22 ± 0.089-1.09 ± 0.089
Week 48-1.17 ± 0.081-1.11 ± 0.080
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.93 · 95% CI -1.15 to -0.70
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.92 · 95% CI -1.16 to -0.68
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.02 · 95% CI -1.40 to -0.63
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.96 · 95% CI -1.19 to -0.74
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.96 · 95% CI -1.20 to -0.72
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4731 · Ls mean difference: -0.05 · 95% CI -0.20 to 0.09
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4055 · Ls mean difference: -0.08 · 95% CI -0.26 to 0.11
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2648 · Ls mean difference: -0.12 · 95% CI -0.34 to 0.09
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5558 · Ls mean difference: -0.06 · 95% CI -0.25 to 0.14
SecondaryChange From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Weeks 16 and 48

The ASQoL was an 18-item questionnaire assessed the amount of restriction participant experienced in daily activities, level of pain and fatigue, and the impact on the participant's emotional state. Each item was scored as 0 (no impact) or 1 (yes - impact). A total score was calculated by summing the items. The total score ranged from 0 (no impact) to 18 (yes-impact), with higher values indicated more impaired health-related quality of life.

Time frame:
Baseline, Weeks 16 and 48
Reported as:
Least squares mean · Units on scale
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Weeks 16 and 48
Units on scaleTofacitinibPlacebo Then Tofacitinib
Week 16-4.03 ± 0.404-2.01 ± 0.405
Week 48-5.97 ± 0.454-4.70 ± 0.451
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.0001 · Ls mean difference: -2.02 · 95% CI -3.03 to -1.01
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0270 · Ls mean difference: -1.26 · 95% CI -2.38 to -0.14
SecondaryChange From Baseline in Short-Form-36 Health Survey-Version 2 Acute (SF-36v2) Score at Weeks 16 and 48

SF-36 v.2 (Acute): 36-item generic health status measure. It measured 8 general health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, mental health. These domains were aggregated into 2 summary scores - physical component summary (PCS), mental component summary (MCS). Four domains comprised PCS score (physical functioning, role-physical, bodily pain, general health) and remaining 4 domains comprised MCS score (vitality, social functioning, role-emotional, mental health). Normalized domain scores, PCS, MCS scores are used in analyses. Component and domain scores were scored by using United States 1998 general population norm. Resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scale and component summary measures had means of 50 and standard deviations of 10. Higher PCS/MCS/domain score represent better health status.

Time frame:
Baseline, Weeks 16 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Short-Form-36 Health Survey-Version 2 Acute (SF-36v2) Score at Weeks 16 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 16: Physical Functioning5.52 ± 0.6653.29 ± 0.665
Week 16: Role-Physical6.13 ± 0.7443.13 ± 0.745
Week 16: Bodily Pain7.93 ± 0.7103.47 ± 0.713
Week 16: General Health5.00 ± 0.6171.76 ± 0.618
Week 16: Vitality5.34 ± 0.8643.56 ± 0.869
Week 16: Social Functioning5.45 ± 0.8352.49 ± 0.837
Week 16: Role-Emotional4.13 ± 1.0202.05 ± 1.017
Week 16: Mental Health3.57 ± 0.8862.49 ± 0.888
Week 16: Physical Component Summary6.69 ± 0.5883.14 ± 0.590
Week 16: Mental Component Summary3.45 ± 0.9142.13 ± 0.915
Week 48: Physical Functioning7.80 ± 0.7756.94 ± 0.766
Week 48: Role-Physical8.66 ± 0.8707.29 ± 0.862
Week 48: Bodily Pain11.67 ± 0.9209.55 ± 0.912
Week 48: General Health6.31 ± 0.7775.10 ± 0.770
Week 48: Vitality9.83 ± 0.9979.28 ± 0.992
Week 48: Social Functioning8.16 ± 0.9236.77 ± 0.915
Week 48: Role-Emotional7.17 ± 1.0046.32 ± 0.989
Week 48: Mental Health7.10 ± 0.9606.45 ± 0.954
Week 48: Physical Component Summary8.81 ± 0.7207.39 ± 0.714
Week 48: Mental Component Summary7.07 ± 0.9266.35 ± 0.920
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.0088 · Ls mean difference: 2.22 · 95% CI 0.56 to 3.88
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.0016 · Ls mean difference: 3.00 · 95% CI 1.15 to 4.85
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = <0.0001 · Ls mean difference: 4.46 · 95% CI 2.69 to 6.23
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = <0.0001 · Ls mean difference: 3.24 · 95% CI 1.70 to 4.78
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.1065 · Ls mean difference: 1.78 · 95% CI -0.38 to 3.94
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.0055 · Ls mean difference: 2.96 · 95% CI 0.88 to 5.05
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.1084 · Ls mean difference: 2.08 · 95% CI -0.46 to 4.61
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.3379 · Ls mean difference: 1.08 · 95% CI -1.13 to 3.29
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = <0.0001 · Ls mean difference: 3.55 · 95% CI 2.09 to 5.02
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.2529 · Ls mean difference: 1.33 · 95% CI -0.95 to 3.61
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.3744 · Ls mean difference: 0.86 · 95% CI -1.04 to 2.76
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2091 · Ls mean difference: 1.36 · 95% CI -0.77 to 3.50
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0654 · Ls mean difference: 2.12 · 95% CI -0.14 to 4.38
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2100 · Ls mean difference: 1.22 · 95% CI -0.69 to 3.12
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.6568 · Ls mean difference: 0.56 · 95% CI -1.90 to 3.01
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2288 · Ls mean difference: 1.39 · 95% CI -0.88 to 3.66
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4955 · Ls mean difference: 0.85 · 95% CI -1.61 to 3.32
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5888 · Ls mean difference: 0.65 · 95% CI -1.71 to 3.01
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1150 · Ls mean difference: 1.42 · 95% CI -0.35 to 3.18
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5347 · Ls mean difference: 0.72 · 95% CI -1.56 to 3.00
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Cervical Rotation Angle at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

BASMI assess axial status and spinal mobility. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component score mapped between 0 and 10, high score=more impairment of axial status, spinal mobility. For cervical rotation angle, participant sit straight on chair with chin level and hands on knees. Blinded assessor place goniometer at top of head in line with nose and ask participant to rotate neck maximally to left, follows with goniometer and record angle between sagittal plane and new plane after rotation. A second reading obtained and both readings recorded. Procedure repeated for right side. Better of two for each side was selected for scoring. Scoring done by calculating mean of left and right measurement and recorded in degrees (range: 0 to 90), higher cervical rotation value=better health status.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Degrees
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Cervical Rotation Angle at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
DegreesTofacitinibPlacebo Then Tofacitinib
Week 22.25 ± 0.7010.95 ± 0.698
Week 43.63 ± 0.7972.07 ± 0.792
Week 86.26 ± 0.8252.44 ± 0.824
Week 126.24 ± 1.0022.92 ± 1.004
Week 167.74 ± 1.0093.00 ± 1.008
Week 247.68 ± 1.1397.49 ± 1.131
Week 327.25 ± 1.0878.23 ± 1.080
Week 407.62 ± 1.2158.34 ± 1.207
Week 487.63 ± 1.2018.23 ± 1.188
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1513 · Ls mean difference: 1.29 · 95% CI -0.48 to 3.06
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1279 · Ls mean difference: 1.56 · 95% CI -0.45 to 3.56
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0003 · Ls mean difference: 3.83 · 95% CI 1.75 to 5.90
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0102 · Ls mean difference: 3.32 · 95% CI 0.79 to 5.84
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0003 · Ls mean difference: 4.73 · 95% CI 2.20 to 7.26
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.8950 · Ls mean difference: 0.19 · 95% CI -2.64 to 3.02
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4732 · Ls mean difference: -0.98 · 95% CI -3.67 to 1.71
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.6359 · Ls mean difference: -0.72 · 95% CI -3.72 to 2.28
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.6894 · Ls mean difference: -0.60 · 95% CI -3.54 to 2.35
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Intermalleolar Distance at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

BASMI assessed axial status and spinal mobility, using linear function. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of intermalleolar distances, participant should lie supine with the knees straight and feet/toes pointing straight up and asked to separate the legs as far as possible and the distance between the medial malleoli was measured (in Centimeters \[cm\] to the nearest 0.1 cm). Distance (in cm) was greater than or equal to 0, with no maximum defined range: higher intermalleolar distance value indicates better health status.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Centimeters
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Intermalleolar Distance at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
CentimetersTofacitinibPlacebo Then Tofacitinib
Week 22.29 ± 0.7330.90 ± 0.730
Week 43.62 ± 0.8610.84 ± 0.856
Week 84.68 ± 0.9791.36 ± 0.976
Week 125.33 ± 1.1061.97 ± 1.108
Week 166.84 ± 1.0842.64 ± 1.082
Week 247.79 ± 1.1774.39 ± 1.174
Week 328.98 ± 1.2215.32 ± 1.215
Week 408.60 ± 1.2294.75 ± 1.222
Week 487.83 ± 1.2334.34 ± 1.222
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1410 · Ls mean difference: 1.39 · 95% CI -0.46 to 3.24
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0122 · Ls mean difference: 2.78 · 95% CI 0.61 to 4.95
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0085 · Ls mean difference: 3.32 · 95% CI 0.86 to 5.79
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0184 · Ls mean difference: 3.36 · 95% CI 0.57 to 6.15
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0026 · Ls mean difference: 4.19 · 95% CI 1.47 to 6.91
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0236 · Ls mean difference: 3.40 · 95% CI 0.46 to 6.35
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0182 · Ls mean difference: 3.66 · 95% CI 0.63 to 6.70
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0133 · Ls mean difference: 3.85 · 95% CI 0.81 to 6.90
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0245 · Ls mean difference: 3.49 · 95% CI 0.45 to 6.52
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Lateral Spinal Flexion at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

BASMI assess axial status, spinal mobility, using linear function. It composed of 5 clinical measures. BASMI - Linear Method score-average of 5 component scores mapped between 0 and 10, with high scores =more impairment of axial status, spinal mobility. For assessment of lateral spinal flexion: participant stand upright with head and back rest against wall as close as possible with shoulders level and feet 30 cm apart and feet parallel. At tip of middle finger, place a mark on thigh. This neutral position recorded. Participant bend sideways without bending knees or lifting heels while attempting to keep shoulders in same position (flexion position). Second mark placed, lateral flexion recorded (left or right as appropriate) using cm tape measure. Two tries for left, two tries for right measured. Result of two tries recorded for left and right separately in cm to nearest 0.1 cm. Distance (in cm) should be \>=0, with no maximum defined range: high value indicates better health status.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Centimeters
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Lateral Spinal Flexion at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
CentimetersTofacitinibPlacebo Then Tofacitinib
Week 20.60 ± 0.200-0.21 ± 0.199
Week 40.96 ± 0.235-0.10 ± 0.233
Week 81.34 ± 0.2380.15 ± 0.237
Week 121.42 ± 0.214-0.21 ± 0.214
Week 161.79 ± 0.269-0.08 ± 0.269
Week 241.70 ± 0.2780.75 ± 0.276
Week 321.90 ± 0.3191.31 ± 0.316
Week 402.15 ± 0.3321.37 ± 0.329
Week 481.64 ± 0.3451.34 ± 0.340
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0018 · Ls mean difference: 0.81 · 95% CI 0.30 to 1.32
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0005 · Ls mean difference: 1.06 · 95% CI 0.47 to 1.65
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0001 · Ls mean difference: 1.19 · 95% CI 0.59 to 1.79
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 1.63 · 95% CI 1.09 to 2.17
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 1.87 · 95% CI 1.20 to 2.55
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0075 · Ls mean difference: 0.95 · 95% CI 0.26 to 1.65
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1489 · Ls mean difference: 0.58 · 95% CI -0.21 to 1.38
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0609 · Ls mean difference: 0.78 · 95% CI -0.04 to 1.61
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4822 · Ls mean difference: 0.30 · 95% CI -0.54 to 1.15
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Lumbar Flexion (Modified Schober) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

BASMI assessed axial status and spinal mobility. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of lumbar flexion, With the participant standing erect and outer edges of feet 30 cm apart, a mark was placed in the midpoint of a line that joins the posterior superior iliac spines (baseline mark). A second mark (A) was placed 10 cm above the baseline mark and a third mark (B) 5 cm below the baseline mark. Then have the participant maximally bend forward, keeping the knees fully extended. With the participant's spine in full flexion, the distance between marks A and B (in cm to the nearest 0.1 cm) was re-measured. Distance (in cm) was greater than or equal to 0, with no maximum defined range. Higher value indicates better health status.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Centimeters
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Lumbar Flexion (Modified Schober) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
CentimetersTofacitinibPlacebo Then Tofacitinib
Week 20.30 ± 0.102-0.07 ± 0.102
Week 40.41 ± 0.102-0.11 ± 0.102
Week 80.32 ± 0.116-0.17 ± 0.115
Week 120.26 ± 0.111-0.22 ± 0.111
Week 160.46 ± 0.115-0.06 ± 0.115
Week 240.51 ± 0.1490.20 ± 0.148
Week 320.64 ± 0.1430.39 ± 0.142
Week 400.58 ± 0.1560.50 ± 0.155
Week 480.45 ± 0.1460.35 ± 0.144
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0047 · Ls mean difference: 0.37 · 95% CI 0.12 to 0.63
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0001 · Ls mean difference: 0.52 · 95% CI 0.26 to 0.77
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0012 · Ls mean difference: 0.49 · 95% CI 0.19 to 0.78
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0008 · Ls mean difference: 0.48 · 95% CI 0.20 to 0.76
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0004 · Ls mean difference: 0.53 · 95% CI 0.24 to 0.81
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0918 · Ls mean difference: 0.32 · 95% CI -0.05 to 0.69
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1600 · Ls mean difference: 0.25 · 95% CI -0.10 to 0.61
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.6776 · Ls mean difference: 0.08 · 95% CI -0.30 to 0.47
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5646 · Ls mean difference: 0.10 · 95% CI -0.25 to 0.46
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Tragus-to-wall Distance at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

BASMI assessed axial status and spinal mobility, using linear function. It composed of 5 clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, cervical rotation. BASMI - Linear Method score was average of 5 individual component scores mapped between 0 and 10, with higher scores indicating more impairment of axial status and spinal mobility. For the assessment of tragus-to-wall distance, participant was placed standing with his/her back against the wall; knees straight; scapulae, buttocks, and heels against wall; and head in as neutral position as possible. The distance between the tragus and wall in cm was measured (to the nearest 0.1 cm) from both the right side and left side at the maximum effort to touch the head against the wall. Distance should be greater than or equal to 0 cm with no defined maximum value, lower tragus-to-wall value indicates better health status.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Centimeters
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Scores: Tragus-to-wall Distance at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
CentimetersTofacitinibPlacebo Then Tofacitinib
Week 2-0.19 ± 0.126-0.24 ± 0.125
Week 4-0.48 ± 0.144-0.07 ± 0.143
Week 8-0.51 ± 0.1770.36 ± 0.177
Week 12-0.40 ± 0.1690.23 ± 0.169
Week 16-0.50 ± 0.1680.09 ± 0.168
Week 24-0.66 ± 0.202-0.03 ± 0.201
Week 32-0.66 ± 0.1790.00 ± 0.178
Week 40-0.60 ± 0.200-0.14 ± 0.199
Week 48-0.73 ± 0.204-0.18 ± 0.202
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.7291 · Ls mean difference: 0.06 · 95% CI -0.26 to 0.37
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0257 · Ls mean difference: -0.41 · 95% CI -0.78 to -0.05
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0002 · Ls mean difference: -0.86 · 95% CI -1.31 to -0.42
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0041 · Ls mean difference: -0.63 · 95% CI -1.05 to -0.20
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0062 · Ls mean difference: -0.59 · 95% CI -1.02 to -0.17
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0140 · Ls mean difference: -0.63 · 95% CI -1.13 to -0.13
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0035 · Ls mean difference: -0.66 · 95% CI -1.11 to -0.22
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0645 · Ls mean difference: -0.47 · 95% CI -0.97 to 0.03
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0341 · Ls mean difference: -0.54 · 95% CI -1.05 to -0.04
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Linear Method Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

The BASMI was used to assess the axial status and spinal mobility (cervical, dorsal and lumbar spine, hips and pelvic soft tissue) and was analyzed using the linear function method. BASMI score composed of five clinical measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober), maximal intermalleolar distance, and cervical rotation. BASMI - Linear Method score was the average of 5 individual component scores mapped between 0 and 10 and thus the BASMI - Linear Method total score ranged from 0 (very good) to 10 (very poor), wherein higher scores indicated more impairment of axial status and spinal mobility; lower scores indicated better health status.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) Linear Method Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 2-0.25 ± 0.044-0.03 ± 0.043
Week 4-0.39 ± 0.053-0.06 ± 0.053
Week 8-0.49 ± 0.059-0.03 ± 0.058
Week 12-0.49 ± 0.058-0.02 ± 0.058
Week 16-0.63 ± 0.060-0.11 ± 0.060
Week 24-0.67 ± 0.068-0.38 ± 0.068
Week 32-0.74 ± 0.069-0.52 ± 0.068
Week 40-0.74 ± 0.074-0.55 ± 0.073
Week 48-0.69 ± 0.074-0.54 ± 0.073
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0001 · Ls mean difference: -0.22 · 95% CI -0.33 to -0.11
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.33 · 95% CI -0.47 to -0.20
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.46 · 95% CI -0.61 to -0.31
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.47 · 95% CI -0.62 to -0.32
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.52 · 95% CI -0.67 to -0.37
  • Tofacitinib vs Placebo Then Tofacitinib · LS mean difference · p = 0.0008 · Ls mean difference: -0.29 · 95% CI -0.46 to -0.12
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0116 · Ls mean difference: -0.22 · 95% CI -0.39 to -0.05
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0416 · Ls mean difference: -0.19 · 95% CI -0.37 to -0.01
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0915 · Ls mean difference: -0.16 · 95% CI -0.34 to 0.03
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

FACIT-F is a 13-item questionnaire (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired), with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three type of scores were derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score was calculated by summing the 13 items (range 0 \[not at all\] to 52 \[very much\]); higher scores represent less fatigue status. In this outcome measure, change from baseline in FACIT-F total score was reported.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 23.16 ± 0.5520.32 ± 0.548
Week 44.80 ± 0.5951.19 ± 0.591
Week 86.46 ± 0.7061.03 ± 0.703
Week 126.25 ± 0.7371.24 ± 0.736
Week 166.54 ± 0.7953.12 ± 0.794
Week 247.42 ± 0.8425.84 ± 0.836
Week 327.90 ± 0.8137.24 ± 0.807
Week 408.67 ± 0.8177.15 ± 0.810
Week 489.54 ± 0.8977.35 ± 0.891
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 2.85 · 95% CI 1.46 to 4.24
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 3.61 · 95% CI 2.11 to 5.10
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 5.42 · 95% CI 3.65 to 7.20
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 5.01 · 95% CI 3.15 to 6.86
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0008 · Ls mean difference: 3.43 · 95% CI 1.44 to 5.42
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1390 · Ls mean difference: 1.58 · 95% CI -0.52 to 3.68
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5217 · Ls mean difference: 0.66 · 95% CI -1.36 to 2.67
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1415 · Ls mean difference: 1.51 · 95% CI -0.51 to 3.54
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0533 · Ls mean difference: 2.19 · 95% CI -0.03 to 4.41
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

FACIT-F is a 13-item (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired) questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-F experience domain score was calculated by summing 5 items: I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy. FACIT-F total experience domain score ranged from 0 (not at all) to 20 (very much), with higher scores represented better (less) fatigue impact on daily functioning. In this outcome measure, change from baseline in FACIT-F experience domain score was reported.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 21.35 ± 0.2750.11 ± 0.274
Week 42.30 ± 0.2980.60 ± 0.296
Week 82.72 ± 0.3310.53 ± 0.330
Week 122.78 ± 0.3430.80 ± 0.344
Week 162.85 ± 0.3571.29 ± 0.357
Week 243.58 ± 0.3842.96 ± 0.382
Week 323.65 ± 0.3703.43 ± 0.367
Week 403.98 ± 0.3753.59 ± 0.371
Week 484.22 ± 0.4033.40 ± 0.400
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0005 · Ls mean difference: 1.25 · 95% CI 0.55 to 1.94
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 1.70 · 95% CI 0.95 to 2.45
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 2.19 · 95% CI 1.35 to 3.02
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 1.98 · 95% CI 1.11 to 2.84
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0007 · Ls mean difference: 1.56 · 95% CI 0.67 to 2.45
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2018 · Ls mean difference: 0.62 · 95% CI -0.33 to 1.58
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.6432 · Ls mean difference: 0.22 · 95% CI -0.70 to 1.13
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4092 · Ls mean difference: 0.39 · 95% CI -0.54 to 1.31
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1070 · Ls mean difference: 0.82 · 95% CI -0.18 to 1.81
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

FACIT-F is a 13-item (felt fatigued, felt weak all over, felt listless \["washed out"\],felt tired, had energy, had trouble starting things as tired, had trouble finishing things as tired, was able to do usual activities, needed to sleep during day, too tired to eat, needed help doing my usual activities, frustrated by being too tired to do things wanted to do, had to limit my social activity because tired) questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-F experience domain score calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless, I feel tired, and I have energy, while FACIT-F impact domain score was calculated by summing the remaining 8 items. FACIT-F impact domain score ranged from 0 (not at all) to 32 (very much), with higher scores represented better (less) fatigue impact on daily functioning. In this outcome measure, change from baseline in FACIT-F impact domain score was reported.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Scores at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 21.79 ± 0.3340.17 ± 0.332
Week 42.47 ± 0.3640.55 ± 0.361
Week 83.73 ± 0.4290.46 ± 0.428
Week 123.45 ± 0.4400.41 ± 0.441
Week 163.68 ± 0.4881.81 ± 0.487
Week 243.84 ± 0.5042.86 ± 0.501
Week 324.25 ± 0.4893.80 ± 0.485
Week 404.70 ± 0.4803.57 ± 0.476
Week 485.32 ± 0.5423.95 ± 0.538
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0002 · Ls mean difference: 1.62 · 95% CI 0.78 to 2.46
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 1.92 · 95% CI 1.00 to 2.84
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 3.26 · 95% CI 2.18 to 4.34
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 3.04 · 95% CI 1.93 to 4.15
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0028 · Ls mean difference: 1.87 · 95% CI 0.65 to 3.09
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1289 · Ls mean difference: 0.97 · 95% CI -0.28 to 2.23
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4698 · Ls mean difference: 0.45 · 95% CI -0.77 to 1.66
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0616 · Ls mean difference: 1.13 · 95% CI -0.06 to 2.32
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0455 · Ls mean difference: 1.37 · 95% CI 0.03 to 2.71
SecondaryChange From Baseline in Patient's Global Assessment of Disease (PGA) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

Participants answered the question, "How active was your spondylitis on average during the last week?. Participant's response was recorded using a numerical rating scale ranged from 0 (Not Active) to 10 (Very Active), with higher scores indicated more severe disease.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Patient's Global Assessment of Disease (PGA) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 2-1.21 ± 0.144-0.32 ± 0.144
Week 4-1.85 ± 0.168-0.63 ± 0.167
Week 8-2.14 ± 0.181-0.42 ± 0.181
Week 12-2.37 ± 0.193-0.65 ± 0.193
Week 16-2.47 ± 0.204-0.91 ± 0.204
Week 24-2.76 ± 0.222-2.21 ± 0.221
Week 32-3.04 ± 0.228-2.43 ± 0.226
Week 40-3.04 ± 0.222-2.50 ± 0.220
Week 48-3.47 ± 0.225-2.94 ± 0.223
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.88 · 95% CI -1.25 to -0.52
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.22 · 95% CI -1.65 to -0.80
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.71 · 95% CI -2.17 to -1.26
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.72 · 95% CI -2.20 to -1.23
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.56 · 95% CI -2.07 to -1.05
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0483 · Ls mean difference: -0.56 · 95% CI -1.11 to -0.00
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0357 · Ls mean difference: -0.60 · 95% CI -1.17 to -0.04
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0508 · Ls mean difference: -0.55 · 95% CI -1.09 to 0.00
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0614 · Ls mean difference: -0.53 · 95% CI -1.08 to 0.03
SecondaryChange From Baseline in Patient's Assessment of Spinal Pain: Total Back Pain at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

Participants marked their level of total back pain on a numerical rating scale (NRS) ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Patient's Assessment of Spinal Pain: Total Back Pain at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 2-1.28 ± 0.145-0.38 ± 0.144
Week 4-2.05 ± 0.164-0.71 ± 0.164
Week 8-2.51 ± 0.173-0.53 ± 0.173
Week 12-2.57 ± 0.192-0.69 ± 0.192
Week 16-2.57 ± 0.191-0.96 ± 0.191
Week 24-2.99 ± 0.206-2.47 ± 0.205
Week 32-3.16 ± 0.212-2.86 ± 0.210
Week 40-3.11 ± 0.217-2.62 ± 0.215
Week 48-3.57 ± 0.220-2.87 ± 0.218
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.89 · 95% CI -1.26 to -0.53
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.34 · 95% CI -1.75 to -0.92
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.98 · 95% CI -2.41 to -1.54
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.89 · 95% CI -2.37 to -1.40
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.62 · 95% CI -2.10 to -1.14
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0492 · Ls mean difference: -0.51 · 95% CI -1.03 to -0.00
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2614 · Ls mean difference: -0.30 · 95% CI -0.82 to 0.22
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0722 · Ls mean difference: -0.49 · 95% CI -1.03 to 0.04
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0121 · Ls mean difference: -0.70 · 95% CI -1.24 to -0.15
SecondaryChange From Baseline in Patient's Assessment of Spinal Pain: Nocturnal Spinal Pain at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

Participants marked their level of nocturnal spinal pain on a NRS ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Patient's Assessment of Spinal Pain: Nocturnal Spinal Pain at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 2-1.24 ± 0.162-0.32 ± 0.161
Week 4-2.15 ± 0.169-0.56 ± 0.167
Week 8-2.61 ± 0.191-0.59 ± 0.190
Week 12-2.60 ± 0.198-0.60 ± 0.199
Week 16-2.67 ± 0.204-0.84 ± 0.204
Week 24-3.07 ± 0.217-2.59 ± 0.215
Week 32-3.17 ± 0.219-2.89 ± 0.217
Week 40-3.20 ± 0.226-2.73 ± 0.224
Week 48-3.52 ± 0.229-3.01 ± 0.227
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.92 · 95% CI -1.33 to -0.51
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.60 · 95% CI -2.02 to -1.17
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -2.02 · 95% CI -2.50 to -1.54
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -2.00 · 95% CI -2.50 to -1.50
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.84 · 95% CI -2.35 to -1.32
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0785 · Ls mean difference: -0.48 · 95% CI -1.02 to 0.06
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.3047 · Ls mean difference: -0.28 · 95% CI -0.82 to 0.26
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1009 · Ls mean difference: -0.47 · 95% CI -1.02 to 0.09
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0764 · Ls mean difference: -0.51 · 95% CI -1.08 to 0.05
SecondaryChange From Baseline in in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

BASFI was a functional index which included 10 items assessing ability of participants to perform normal daily activities. The first 8 questions/items consider activities related to functional anatomy. The final 2 questions/items assess the participants' ability to cope with everyday life. Each item was scored on a scale of 0=easy to 10=impossible. The BASFI total score was calculated as the average score of these 10 individual items. BASFI total score ranged from 0 (easy) to 10 (impossible), where higher scores indicated more severe disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 2-0.87 ± 0.125-0.45 ± 0.124
Week 4-1.35 ± 0.140-0.58 ± 0.139
Week 8-1.79 ± 0.158-0.69 ± 0.157
Week 12-2.01 ± 0.164-0.71 ± 0.164
Week 16-2.05 ± 0.170-0.82 ± 0.169
Week 24-2.25 ± 0.191-1.91 ± 0.190
Week 32-2.42 ± 0.188-2.16 ± 0.187
Week 40-2.62 ± 0.192-2.23 ± 0.191
Week 48-2.61 ± 0.196-2.32 ± 0.195
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0089 · Ls mean difference: -0.42 · 95% CI -0.73 to -0.11
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.77 · 95% CI -1.12 to -0.42
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.10 · 95% CI -1.50 to -0.70
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.29 · 95% CI -1.71 to -0.88
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.23 · 95% CI -1.66 to -0.80
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1686 · Ls mean difference: -0.33 · 95% CI -0.81 to 0.14
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2800 · Ls mean difference: -0.26 · 95% CI -0.72 to 0.21
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1135 · Ls mean difference: -0.39 · 95% CI -0.86 to 0.09
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2496 · Ls mean difference: -0.29 · 95% CI -0.77 to 0.20
SecondaryChange From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Inflammation (Morning Stiffness) Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

The BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity. BASDAI inflammation score was derived by taking mean of the responses of question 5 and 6 and ranged from 0 (none) to 10 (very severe), where higher score indicated more inflammation (morning stiffness).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Inflammation (Morning Stiffness) Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 2-1.33 ± 0.149-0.49 ± 0.149
Week 4-2.08 ± 0.164-0.60 ± 0.163
Week 8-2.52 ± 0.178-0.91 ± 0.178
Week 12-2.71 ± 0.185-0.84 ± 0.186
Week 16-2.69 ± 0.185-0.97 ± 0.185
Week 24-2.99 ± 0.193-2.48 ± 0.193
Week 32-3.11 ± 0.200-2.61 ± 0.199
Week 40-3.28 ± 0.204-2.64 ± 0.203
Week 48-3.46 ± 0.214-2.90 ± 0.213
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.84 · 95% CI -1.22 to -0.47
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.48 · 95% CI -1.89 to -1.07
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.61 · 95% CI -2.06 to -1.16
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.87 · 95% CI -2.34 to -1.40
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.72 · 95% CI -2.18 to -1.25
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0385 · Ls mean difference: -0.51 · 95% CI -0.99 to -0.03
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0463 · Ls mean difference: -0.50 · 95% CI -1.00 to -0.01
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0126 · Ls mean difference: -0.65 · 95% CI -1.15 to -0.14
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0372 · Ls mean difference: -0.56 · 95% CI -1.09 to -0.03
SecondaryPercentage of Participants Achieving ASAS 5/6 Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

ASAS 5/6 consists of 6 domains: 4 used in ASAS20 - PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), Spinal Pain (total back pain) (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), CRP (was measured in mg per liter) and Spinal mobility was measured in centimeter and calculated as mean of right and left measurements of lateral spinal flexion from BASMI. ASAS 5/6: defined as \>=20% improvement in at least 5 domains.

Time frame:
Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS 5/6 Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Week 216.542.94
Week 435.346.62
Week 841.358.09
Week 1245.869.56
Week 1643.617.35
Week 2449.6244.12
Week 3251.1353.68
Week 4048.8750.74
Week 4843.6144.85
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0001 · Difference in percentage: 13.60 · 95% CI 6.68 to 20.52
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 28.79 · 95% CI 19.78 to 37.80
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 33.31 · 95% CI 23.84 to 42.78
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 36.37 · 95% CI 26.67 to 46.07
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 36.34 · 95% CI 27.05 to 45.63
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.3498 · Difference in percentage: 5.60 · 95% CI -6.14 to 17.35
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.6835 · Difference in percentage: -2.40 · 95% CI -13.96 to 9.15
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.7704 · Difference in percentage: -1.75 · 95% CI -13.47 to 9.98
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.8492 · Difference in percentage: -1.13 · 95% CI -12.80 to 10.53
SecondaryPercentage of Participants Achieving ASAS Partial Remission at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

Partial remission was defined as a score of 2 or less (on a scale of 0-10, where 0=no disease activity and 10=high disease activity) in each of the 4 domains in ASAS. These 4 domains included: PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity).

Time frame:
Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS Partial Remission at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Week 22.260
Week 44.510
Week 87.521.47
Week 1215.042.94
Week 1615.042.94
Week 2421.8011.76
Week 3223.3115.44
Week 4024.0616.91
Week 4823.3117.65
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.1692 · Difference in percentage: 2.24 · 95% CI -0.95 to 5.43
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0289 · Difference in percentage: 4.46 · 95% CI 0.46 to 8.46
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0199 · Difference in percentage: 6.02 · 95% CI 0.95 to 11.09
  • Tofacitinib vs Placebo Then Tofacitinib · Difference in percentage · p = 0.0005 · Difference in percentage: 12.03 · 95% CI 5.26 to 18.81
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0005 · Difference in percentage: 12.05 · 95% CI 5.29 to 18.80
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0253 · Difference in percentage: 10.03 · 95% CI 1.24 to 18.83
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0950 · Difference in percentage: 7.93 · 95% CI -1.38 to 17.24
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.1377 · Difference in percentage: 7.21 · 95% CI -2.31 to 16.73
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.2472 · Difference in percentage: 5.68 · 95% CI -3.94 to 15.30
SecondaryChange From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

The BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 2-1.25 ± 0.127-0.52 ± 0.126
Week 4-1.95 ± 0.146-0.67 ± 0.145
Week 8-2.32 ± 0.164-0.82 ± 0.163
Week 12-2.49 ± 0.172-0.81 ± 0.172
Week 16-2.55 ± 0.175-1.11 ± 0.174
Week 24-2.81 ± 0.185-2.41 ± 0.184
Week 32-2.94 ± 0.191-2.53 ± 0.190
Week 40-3.09 ± 0.193-2.63 ± 0.192
Week 48-3.30 ± 0.199-2.80 ± 0.197
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.73 · 95% CI -1.05 to -0.41
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.28 · 95% CI -1.65 to -0.91
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.50 · 95% CI -1.92 to -1.09
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.68 · 95% CI -2.11 to -1.24
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -1.44 · 95% CI -1.88 to -1.00
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0880 · Ls mean difference: -0.40 · 95% CI -0.86 to 0.06
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0921 · Ls mean difference: -0.41 · 95% CI -0.88 to 0.07
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0597 · Ls mean difference: -0.46 · 95% CI -0.94 to 0.02
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0492 · Ls mean difference: -0.49 · 95% CI -0.99 to -0.00
SecondaryPercentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

BASDAI was a validated questionnaire that consisted of 6 questions pertaining to the 5 major symptoms of AS: fatigue; spinal pain; peripheral arthritis; enthesitis, intensity of morning stiffness and duration of morning stiffness. Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. BASDAI score was calculated by computing mean of questions 5 and 6 and adding it to sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0= none to 10= very severe, where higher score indicated high disease activity. BASDAI50 response was defined as decrease of \>=50% from Baseline in BASDAI score at specified time points. Percentage of participants with BASDAI 50 response at specified weeks are reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Week 212.033.68
Week 429.326.62
Week 839.8511.03
Week 1242.8611.03
Week 1642.8617.65
Week 2447.3736.76
Week 3251.1341.18
Week 4052.6339.71
Week 4851.1340.44
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0116 · Difference in percentage: 8.31 · 95% CI 1.86 to 14.77
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 22.74 · 95% CI 13.99 to 31.49
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 28.87 · 95% CI 19.09 to 38.66
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 31.93 · 95% CI 22.28 to 41.58
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 25.28 · 95% CI 14.82 to 35.75
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0683 · Difference in percentage: 10.71 · 95% CI -0.80 to 22.23
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0906 · Difference in percentage: 10.05 · 95% CI -1.59 to 21.70
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0282 · Difference in percentage: 13.03 · 95% CI 1.39 to 24.66
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0719 · Difference in percentage: 10.77 · 95% CI -0.96 to 22.49
SecondaryPercentage of Participants With Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Clinically Important Improvement Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) clinically important improvement was defined as decrease from Baseline of \>=1.1 units in ASDAS(CRP) score.

Time frame:
Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Clinically Important Improvement Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Week 239.396.62
Week 453.0312.50
Week 859.8514.71
Week 1260.6115.44
Week 1661.3619.12
Week 2465.1560.29
Week 3265.9161.76
Week 4063.6457.35
Week 4858.3352.94
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 32.79 · 95% CI 23.48 to 42.11
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 40.53 · 95% CI 30.37 to 50.70
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 45.22 · 95% CI 35.03 to 55.41
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 45.23 · 95% CI 34.97 to 55.49
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 42.30 · 95% CI 31.73 to 52.88
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.3967 · Difference in percentage: 4.96 · 95% CI -6.51 to 16.42
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.4442 · Difference in percentage: 4.34 · 95% CI -6.78 to 15.46
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.2810 · Difference in percentage: 6.38 · 95% CI -5.22 to 17.97
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.3514 · Difference in percentage: 5.54 · 95% CI -6.12 to 17.20
SecondaryPercentage of Participants Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Major Improvement Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) major improvement was defined as a response if improvement (decrease) from Baseline in ASDAS(CRP) of \>=2.0 units.

Time frame:
Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Major Improvement Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Week 28.940.00
Week 417.891.55
Week 822.762.33
Week 1226.023.10
Week 1630.084.65
Week 2434.1524.81
Week 3236.5934.11
Week 4039.0231.78
Week 4833.3328.68
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0013 · Difference in percentage: 8.84 · 95% CI 3.46 to 14.21
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 16.25 · 95% CI 9.13 to 23.36
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 20.31 · 95% CI 12.41 to 28.20
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 22.77 · 95% CI 14.46 to 31.08
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 25.28 · 95% CI 16.47 to 34.10
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0941 · Difference in percentage: 9.41 · 95% CI -1.61 to 20.43
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.6727 · Difference in percentage: 2.52 · 95% CI -9.17 to 14.21
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.2213 · Difference in percentage: 7.29 · 95% CI -4.39 to 18.98
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.4137 · Difference in percentage: 4.70 · 95% CI -6.58 to 15.98
SecondaryPercentage of Participants Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Inactive Disease Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

ASDAS(CRP) was derived using BASDAI (6-item questionnaire measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity) and PGA (measure disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity) and by using the following formula, 0.121 x Back Pain (Q2 of BASDAI) + 0.058 x Duration of Morning Stiffness (Q6 of BASDAI) + 0.110 x PGA + 0.073 x Peripheral Pain/Swelling (Q3 of BASDAI) + 0.579 x Ln(hsCRP mg/L + 1). If hsCRP values were smaller than 2 mg/L, they were set to 2 mg/L in the formula. The range of score was \>= 0.636 to no defined upper limit. A negative change from baseline value indicates decrease in disease activity; a positive change from baseline value indicates increase in disease activity. ASDAS(CRP) inactive disease is defined as a response if actual ASDAS(CRP) was \<1.3 units.

Time frame:
Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein (ASDAS[CRP]) Inactive Disease Response at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Percentage of participantsTofacitinibPlacebo Then Tofacitinib
Week 20.750.00
Week 43.760.00
Week 86.020.74
Week 1211.280.74
Week 166.770.00
Week 2412.7811.76
Week 3218.0513.24
Week 4017.2916.91
Week 4815.0413.24
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.5518 · Difference in percentage: 0.75 · 95% CI -1.73 to 3.24
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0524 · Difference in percentage: 3.72 · 95% CI -0.04 to 7.47
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0216 · Difference in percentage: 5.25 · 95% CI 0.77 to 9.73
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0003 · Difference in percentage: 10.48 · 95% CI 4.80 to 16.17
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.0047 · Difference in percentage: 6.69 · 95% CI 2.05 to 11.33
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.7883 · Difference in percentage: 1.07 · 95% CI -6.74 to 8.88
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.2708 · Difference in percentage: 4.85 · 95% CI -3.78 to 13.48
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.9226 · Difference in percentage: 0.44 · 95% CI -8.48 to 9.36
  • Tofacitinib vs Placebo Then Tofacitinib · Cochran-Mantel-Haenszel · p = 0.6630 · Difference in percentage: 1.84 · 95% CI -6.44 to 10.13
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Weeks 4, 8, 12, 16, 24, 32, 40 and 48

The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Sites assessed included 1st costochondral joint (left \[l\]/right \[r\]), 7th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. Each site was graded for the presence (1) and absence (0) of tenderness yielding total MASES score ranging from 0 (no tenderness) to 13 (worst possible score) with higher score indicated more severe tenderness.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Weeks 4, 8, 12, 16, 24, 32, 40 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 4-1.42 ± 0.264-0.59 ± 0.244
Week 8-2.02 ± 0.275-1.28 ± 0.255
Week 12-1.89 ± 0.289-1.17 ± 0.271
Week 16-1.94 ± 0.288-1.41 ± 0.272
Week 24-2.50 ± 0.251-2.32 ± 0.240
Week 32-2.73 ± 0.204-2.54 ± 0.200
Week 40-2.73 ± 0.189-2.75 ± 0.183
Week 48-2.87 ± 0.225-2.56 ± 0.222
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0099 · Ls mean difference: -0.84 · 95% CI -1.47 to -0.20
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0275 · Ls mean difference: -0.74 · 95% CI -1.40 to -0.08
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0420 · Ls mean difference: -0.72 · 95% CI -1.41 to -0.03
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1309 · Ls mean difference: -0.53 · 95% CI -1.22 to 0.16
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5566 · Ls mean difference: -0.18 · 95% CI -0.78 to 0.42
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4497 · Ls mean difference: -0.19 · 95% CI -0.68 to 0.30
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.9272 · Ls mean difference: 0.02 · 95% CI -0.43 to 0.47
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2539 · Ls mean difference: -0.31 · 95% CI -0.85 to 0.23
SecondaryChange From Baseline in Swollen Joint Count (SJC) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

Swollen joint count was an assessment on 44 joints (sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals, thumb interphalangeal, proximal interphalangeals, knees, ankles, and metatarsophalangeals). Each joint was assessed for swelling as: Present or Absent. Artificial joints were not assessed

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Joint count
Change From Baseline in Swollen Joint Count (SJC) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Joint countTofacitinibPlacebo Then Tofacitinib
Week 2-1.71 ± 0.376-2.09 ± 0.358
Week 4-1.90 ± 0.418-2.23 ± 0.398
Week 8-2.39 ± 0.456-2.45 ± 0.438
Week 12-2.79 ± 0.428-2.45 ± 0.419
Week 16-3.35 ± 0.475-2.79 ± 0.465
Week 24-2.81 ± 0.346-3.32 ± 0.335
Week 32-2.45 ± 0.357-3.21 ± 0.341
Week 40-3.04 ± 0.289-3.34 ± 0.274
Week 48-3.31 ± 0.176-3.82 ± 0.174
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4379 · Ls mean difference: 0.37 · 95% CI -0.58 to 1.33
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5340 · Ls mean difference: 0.33 · 95% CI -0.73 to 1.39
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.9148 · Ls mean difference: 0.06 · 95% CI -1.10 to 1.22
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5409 · Ls mean difference: -0.34 · 95% CI -1.43 to 0.76
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.3555 · Ls mean difference: -0.57 · 95% CI -1.78 to 0.65
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2485 · Ls mean difference: 0.51 · 95% CI -0.36 to 1.38
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0866 · Ls mean difference: 0.76 · 95% CI -0.11 to 1.63
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4101 · Ls mean difference: 0.30 · 95% CI -0.42 to 1.01
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0237 · Ls mean difference: 0.50 · 95% CI 0.07 to 0.94
SecondaryChange From Baseline in Spinal Mobility (Chest Expansion ) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48

Chest expansion (measured in centimeters (cm), is defined as the difference in the thoracic circumference during full expiration versus full inspiration. This was measured at the 4th intercostal space. The difference between maximal inspiration and expiration of the two attempts was recorded. The better of the two attempts was used to calculate chest expansion which was defined to be greater than or equal to 0 cm with no defined maximum/upper limit. Greater chest circumference corresponds to higher score indicated more spinal mobility/better health status (measured as Chest Expansion in cm).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
Reported as:
Least squares mean · Centimeter
Change From Baseline in Spinal Mobility (Chest Expansion ) at Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
CentimeterTofacitinibPlacebo Then Tofacitinib
Week 20.22 ± 0.084-0.09 ± 0.083
Week 40.25 ± 0.094-0.07 ± 0.094
Week 80.46 ± 0.1140.22 ± 0.114
Week 120.57 ± 0.1020.25 ± 0.102
Week 160.59 ± 0.1280.38 ± 0.127
Week 240.62 ± 0.1330.63 ± 0.132
Week 320.61 ± 0.1490.71 ± 0.148
Week 400.75 ± 0.1320.68 ± 0.131
Week 480.50 ± 0.1270.47 ± 0.125
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0043 · Ls mean difference: 0.31 · 95% CI 0.10 to 0.52
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0072 · Ls mean difference: 0.33 · 95% CI 0.09 to 0.56
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.1101 · Ls mean difference: 0.23 · 95% CI -0.05 to 0.52
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0147 · Ls mean difference: 0.32 · 95% CI 0.06 to 0.58
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2032 · Ls mean difference: 0.21 · 95% CI -0.11 to 0.53
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.9345 · Ls mean difference: -0.01 · 95% CI -0.34 to 0.32
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5968 · Ls mean difference: -0.10 · 95% CI -0.47 to 0.27
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.7047 · Ls mean difference: 0.06 · 95% CI -0.26 to 0.39
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.8070 · Ls mean difference: 0.04 · 95% CI -0.27 to 0.35
SecondaryChange From Baseline in EuroQol 5 Dimensions 3 Levels (EQ-5D-3L) Score at Weeks 16 and 48

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions. Participants rated 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The mean of the summed score ranged from 1 to 3 with "1" corresponding to no problems and "3" corresponding to severe problems in the 5 dimensions, where higher score indicates more severe problems.

Time frame:
Baseline, Weeks 16 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in EuroQol 5 Dimensions 3 Levels (EQ-5D-3L) Score at Weeks 16 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 16: Mobility-0.23 ± 0.044-0.06 ± 0.044
Week 16: Self-Care-0.21 ± 0.043-0.20 ± 0.043
Week 16: Usual Activities-0.18 ± 0.046-0.09 ± 0.046
Week 16: Pain/Discomfort-0.30 ± 0.036-0.12 ± 0.036
Week 16: Anxiety/Depression-0.11 ± 0.048-0.10 ± 0.048
Week 48: Mobility-0.32 ± 0.051-0.26 ± 0.050
Week 48: Self-Care-0.33 ± 0.048-0.33 ± 0.047
Week 48: Usual Activities-0.32 ± 0.053-0.34 ± 0.053
Week 48: Pain/Discomfort-0.37 ± 0.047-0.36 ± 0.047
Week 48: Anxiety/Depression-0.17 ± 0.054-0.21 ± 0.053
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.0030 · Ls mean difference: -0.17 · 95% CI -0.28 to -0.06
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.8970 · Ls mean difference: -0.01 · 95% CI -0.11 to 0.10
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.1437 · Ls mean difference: -0.09 · 95% CI -0.20 to 0.03
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = <0.0001 · Ls mean difference: -0.18 · 95% CI -0.27 to -0.09
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.8445 · Ls mean difference: -0.01 · 95% CI -0.13 to 0.11
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.3473 · Ls mean difference: -0.06 · 95% CI -0.19 to 0.07
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.9834 · Ls mean difference: 0.00 · 95% CI -0.12 to 0.12
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.7364 · Ls mean difference: 0.02 · 95% CI -0.11 to 0.15
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.8075 · Ls mean difference: -0.01 · 95% CI -0.13 to 0.10
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.5461 · Ls mean difference: 0.04 · 95% CI -0.09 to 0.17
SecondaryChange From Baseline in EuroQol Visual Analogue Scale (EQ-VAS) Score (mm) at Weeks 16 and 48

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions. Its second part included EQ-VAS. EQ-VAS recorded the participant's self-rated health on a VAS ranging from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state), with higher scores indicating better health state.

Time frame:
Baseline, Weeks 16 and 48
Reported as:
Least squares mean · Millimeter (mm)
Change From Baseline in EuroQol Visual Analogue Scale (EQ-VAS) Score (mm) at Weeks 16 and 48
Millimeter (mm)TofacitinibPlacebo Then Tofacitinib
Week 1613.00 ± 1.8402.89 ± 1.840
Week 4820.64 ± 1.87918.00 ± 1.862
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = <0.0001 · Ls mean difference: 10.11 · 95% CI 5.52 to 14.70
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2608 · Ls mean difference: 2.63 · 95% CI -1.97 to 7.24
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to Health Problem at Weeks 16 and 48

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent work time missed due to health problem was a subscale and calculated as: Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity.

Time frame:
Baseline, Weeks 16 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to Health Problem at Weeks 16 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 16-3.65 ± 2.6590.88 ± 2.622
Week 48-8.10 ± 2.136-5.79 ± 2.047
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = 0.1784 · Ls mean difference: -4.53 · 95% CI -11.15 to 2.09
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.3651 · Ls mean difference: -2.31 · 95% CI -7.34 to 2.72
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working Due to Health Problem at Weeks 16 and 48

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent Impairment while Working due to Health Problem was a subscale and calculated as: Q5/10 for those who were currently employed and actually worked in the past 7 days. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity.

Time frame:
Baseline, Weeks 16 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working Due to Health Problem at Weeks 16 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 16-19.83 ± 2.274-6.94 ± 2.303
Week 48-25.35 ± 2.769-23.00 ± 2.656
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = <0.0001 · Ls mean difference: -12.89 · 95% CI -18.59 to -7.19
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.4788 · Ls mean difference: -2.36 · 95% CI -8.92 to 4.21
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment Due to Health Problem at Weeks 16 and 48

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent overall work impairment due to health problem was a subscale and calculated as: Q2/(Q2+Q4)+\[(1- Q2/(Q2+Q4))×(Q5/10)\] for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment.

Time frame:
Baseline, Weeks 16 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment Due to Health Problem at Weeks 16 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 16-21.49 ± 2.508-7.64 ± 2.559
Week 48-27.63 ± 3.005-23.22 ± 2.890
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = <0.0001 · Ls mean difference: -13.85 · 95% CI -20.18 to -7.52
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.2244 · Ls mean difference: -4.41 · 95% CI -11.56 to 2.74
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment Due to Health Problem at Weeks 16 and 48

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which Ankylosing Spondylitis affected work productivity and regular activities over the past 7 days. The questions are as follows: Q1 = currently employed; Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). Percent activity impairment due to health problem was a subscale and calculated as: Q6/10 for all respondents. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment.

Time frame:
Baseline, Weeks 16 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment Due to Health Problem at Weeks 16 and 48
Units on a scaleTofacitinibPlacebo Then Tofacitinib
Week 16-19.03 ± 1.969-5.63 ± 1.968
Week 48-27.37 ± 2.339-19.77 ± 2.310
Statistical analysis
  • Tofacitinib vs Placebo Then Tofacitinib · ANCOVA · p = <0.0001 · Ls mean difference: -13.40 · 95% CI -18.30 to -8.50
  • Tofacitinib vs Placebo Then Tofacitinib · Mixed Models Analysis · p = 0.0095 · Ls mean difference: -7.60 · 95% CI -13.32 to -1.88

Adverse events

Collected over For the first 2 arms: (tofacitinib and Placebo [up to Week 16]): Baseline to Week 16 and for the next 2 arms (tofacitinib and placebo then tofacitinib [Day 1 to Week 48]): Baseline to Week 48. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib: Up to Week 160/133 (0%)2/133 (1.5%)23/133 (17.3%)
Placebo: Up to Week 160/136 (0%)1/136 (0.7%)26/136 (19.1%)
Tofacitinib: Day 1 to Week 480/133 (0%)7/133 (5.3%)51/133 (38.3%)
Placebo Then Tofacitinib: Day 1 to Week 480/136 (0%)2/136 (1.5%)52/136 (38.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTofacitinib: Up to Week 16Placebo: Up to Week 16Tofacitinib: Day 1 to Week 48Placebo Then Tofacitinib: Day 1 to Week 48
HypoacusisEar and labyrinth disorders1/1330/1361/1330/136
Abdominal adhesionsGastrointestinal disorders0/1330/1361/1330/136
Meningitis asepticInfections and infestations1/1330/1361/1330/136
Rib fractureInjury, poisoning and procedural complications0/1330/1361/1330/136
MigraineNervous system disorders0/1330/1361/1330/136
UreterolithiasisRenal and urinary disorders0/1330/1361/1330/136
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1330/1361/1330/136
Subcutaneous emphysemaSkin and subcutaneous tissue disorders0/1330/1361/1330/136
Hyperplastic cholecystopathyHepatobiliary disorders0/1330/1361/1330/136
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/1330/1360/1331/136
Most frequent other events
Most frequent other events
EventTofacitinib: Up to Week 16Placebo: Up to Week 16Tofacitinib: Day 1 to Week 48Placebo Then Tofacitinib: Day 1 to Week 48
Upper respiratory tract infectionInfections and infestations14/13310/13621/13318/136
NasopharyngitisInfections and infestations9/13310/13611/13317/136
DiarrhoeaGastrointestinal disorders0/1330/13610/1338/136
ArthralgiaMusculoskeletal and connective tissue disorders1/1338/1362/1339/136
Alanine aminotransferase increasedInvestigations0/1330/1368/1332/136
Protein urine presentInvestigations0/1330/1368/1334/136
HeadacheNervous system disorders0/1330/1365/1337/136
Abdominal pain upperGastrointestinal disorders0/1330/1362/1337/136

Baseline characteristics

Safety analysis set: included all participants who were randomized and received at least one dose of the investigational product (that is \[i.e.\], tofacitinib or placebo).

Age, Continuous
Age, Continuous(Years)TofacitinibPlacebo Then TofacitinibTotal
Mean42.2 ± 11.8540.0 ± 11.0641.1 ± 11.49
Sex: Female, Male
Sex: Female, Male(Participants)TofacitinibPlacebo Then TofacitinibTotal
Female172845
Male116108224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TofacitinibPlacebo Then TofacitinibTotal
White107106213
Asian253055
Not reported101
08

Study locations

99 sites
  • Rheumatology Associates of North Alabama, PC
    Huntsville, Alabama 35801, United States
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Gilbert, Arizona 85297, United States
  • Medvin Clinical Research
    Covina, California 91722, United States
  • Rheumatology Center of San Diego PC
    San Diego, California 92128, United States
  • University of California, San Francisco Medical Center
    San Francisco, California 94143, United States
  • Robin K. Dore, MD, Inc.
    Tustin, California 92780, United States
  • New England Research Associates, LLC
    Bridgeport, Connecticut 06606, United States
  • Advanced Radiology
    Stamford, Connecticut 06902, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Southcoast Research Center, Inc.
    Miami, Florida 33136, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Bluegrass Community Research, Inc
    Lexington, Kentucky 40504, United States
  • Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • M3-Emerging Medical Research, LLC
    Durham, North Carolina 27704, United States
  • Paramount Medical Research and Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology
    Summerville, South Carolina 29486, United States
  • Precision Comprehensive Clinical Research Solutions
    Colleyville, Texas 76034, United States
  • Adriana Pop-Moody MD - Clinic PA
    Corpus Christi, Texas 78404, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Clinical Research Unit
    Houston, Texas 77030, United States
  • Investigational Drug Services
    Houston, Texas 77030, United States
  • Memorial Hermann Hospital Imaging
    Houston, Texas 77030, United States
  • Southwest Rheumatology Research LLC
    Mesquite, Texas 75150, United States
  • Trinity Universal Research Associates, Inc.
    Plano, Texas 75024, United States
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • Pacific Radiology,
    Maroochydore, Queensland 4558, Australia
  • Rheumatology Research Unit Sunshine Coast
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research Pty. Ltd.
    Camberwell, Victoria 3124, Australia
  • Melbourne Radiology Clinic
    East Melbourne, Victoria 3002, Australia
  • SKG Radiology
    Subiaco, Western Australia 6008, Australia
  • Western Cardiology
    Subiaco, Western Australia 6008, Australia
  • RK Will Pty Ltd
    Victoria Park, Western Australia 6100, Australia
  • Multiprofile Hospital for active treatment "Kaspela" EOOD
    Plovdiv, 4002, Bulgaria
  • Diagnostic-Consulting Center XVII - Sofia
    Sofia, 1505, Bulgaria
  • Medical Centre Synexus Sofia EOOD
    Sofia, 1784, Bulgaria
  • Centre de Recherche Musculo-Squelettique
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.
    Quebec, G1V 3M7, Canada
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • The Third Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510630, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • The First Affiliated Hosptial of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • Rheumatology and Immunology Department, Shanghai Changzheng Hospital
    Shanghai, 200003, China
  • Lekarna Rezidence Nova Karolina
    Ostrava, 702 00, Czechia
  • CCBR Ostrava s.r.o.
    Ostrava, 70200, Czechia
  • BENU Lekarna
    Pardubice, 530 02, Czechia
  • CCR, Czech a.s.
    Pardubice, 530 02, Czechia
  • Lekarna Hradebni, s.r.o.
    Uherske Hradiste, 686 01, Czechia
  • Uherskohradistska nemocnice, a.s.
    Uherske Hradiste, 686 06, Czechia
  • Medical Plus s.r.o.
    Uherske Hradiste, 68601, Czechia
  • CHRU de Tours, Hopital Trousseau
    TOURS Cedex 9, 37044, France
  • Qualiclinic K ft
    Budapest, 1036, Hungary
  • Pest megyei Flór Ferenc Kórház, Reumatológia-és Fizioterápiás Osztály
    Kistarcsa, 2143, Hungary
  • VITAL MEDICAL CENTER (VITÁL-MEDICINA Kft.)
    Veszprém, 8200, Hungary
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
  • Hanyang University Seoul Hospital
    Seoul, 04763, Korea, Republic of
  • Geo Medical Sp. z.o.o Szpital Geo Medical
    Katowice, 40-042, Poland
  • Moja Przychodnia
    Katowice, 40-057, Poland
  • C.M. Silmedic Sp. z o.o.
    Katowice, 40-282, Poland
  • Malopolskie Badania Kliniczne Sp. z o.o. s.k.
    Krakow, 30-040, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA
    Krakow, 30-053, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-363, Poland
  • Centrum Medyczne LUX MED
    Krakow, 30-415, Poland
  • Malopolskie Centrum Medyczne S.C.
    Krakow, 30-510, Poland
  • Szpital Uniwersytecki w Krakowie, Zaklad Radiologii
    Krakow, 31-066, Poland
  • Top Medical
    Lublin, 20-601, Poland
  • Zespol Poradni Specjalistycznych REUMED, Wallenroda Filia nr 1
    Lublin, 20-607, Poland
  • NZOZ JAMED Pracownia Rentgenowska Jerema Antoszewski
    Poznan, 61-397, Poland
  • Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj
    Poznan, 61-397, Poland
  • Klinika Alfa
    Sochaczew, 96-500, Poland
  • RCMed Oddzial Sochaczew
    Sochaczew, 96-500, Poland
  • Szpital Powiatowy w Sochaczewie
    Sochaczew, 96-500, Poland
  • Szpital Sw. Elzbiety, Mokotowskie Centrum Medyczne, Zaklad Diagnostyki
    Warszawa, 02-616, Poland
  • "Reumatika - Centrum Reumatologii" NZOZ
    Warszawa, 02-691, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52-416, Poland
  • Centrum Medyczne Medix
    Wroclaw, 53-413, Poland
  • Limited Liability Company Medical Center "Rheuma-Med"
    Kemerovo, 650070, Russian Federation
  • State Budgetary Healthcare Institution "Orenburg Regional Clinical Hospital"
    Orenburg, 460018, Russian Federation
  • Limited Liability Company "Sanavita"
    Saint-Petersburg, 195257, Russian Federation
  • State Healthcare Institution "Regional Clinical Hospital"
    Saratov, 410053, Russian Federation
  • RSBHI "Smolensk Regional Clinical Hospital"
    Smolensk, 214018, Russian Federation
  • Limited Liability Company "BioMed"
    Vladimir, 600005, Russian Federation
  • Ankara Universitesi Tip Fakultesi Ibn-i Sina Hastanesi
    Ankara, 06100, Turkey
  • Ankara Universitesi Tip Fakultesi, Ibn-i Sina Hastanesi
    Ankara, 06100, Turkey
  • Hacettepe Universitesi Tip Fakultesi, Ic Hastaliklari Anabilim
    Ankara, 06230, Turkey
  • Istanbul Universitesi Istanbul Tip Fakultesi, Ic Hastaliklari
    Istanbul, 34093, Turkey
  • Istanbul Universitesi Istanbul Tip Fakultesi
    Istanbul, 34093, Turkey
  • Marmara Univ. Istanbul Pendik Egitim ve Arastirma Hastanesi
    Istanbul, 34899, Turkey
  • Izmir Katip Celebi Univ Ataturk Egitim ve Arastirma Hastanesi
    Izmir, 35360, Turkey
  • Izmir Katip Celebi Univ. Ataturk Egitim ve Arastirma Hastanesi
    Izmir, 35360, Turkey
  • Kyiv City Clinical Hospital # 3, Rheumatology Department
    Kyiv, 02125, Ukraine
  • Lviv Communal Clinical Hospital #4, Rheumatology department
    Lviv, 79011, Ukraine
  • Military-Medical Clinical Center (Clinical Hospital with 200 beds) of State Border Guard Service of
    Lviv, 79014, Ukraine
  • Ternopil University Hospital, Department of Rheumatology,
    Ternopil, 46002, Ukraine
  • Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrohov, rheumatology department,
    Vinnytsia, 21018, Ukraine
09

References and documents

Publications

  • Cella D, Lenderking WR, Chongpinitchai P, Bushmakin AG, Dina O, Wang L, Cappelleri JC, Navarro-Compan V. Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis. J Patient Rep Outcomes. 2022 Sep 23;6(1):100. doi: 10.1186/s41687-022-00508-0. PubMed 36138330 ↗
  • Navarro-Compan V, Wei JC, Van den Bosch F, Magrey M, Wang L, Fleishaker D, Cappelleri JC, Wang C, Wu J, Dina O, Fallon L, Strand V. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022 Jun;8(2):e002253. doi: 10.1136/rmdopen-2022-002253. PubMed 35654457 ↗
  • Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O, Fallon L, Kanik KS, van der Heijde D. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Aug;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601. Epub 2021 Apr 27. PubMed 33906853 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Dec 2019, 18 months.

Results were first posted in Jan 2021, 1 year after primary completion.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 18 months is below that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2018
First posted
Apr 18, 2018
StartActual
Jun 7, 2018
Primary completionActual
Dec 19, 2019
CompletionActual
Aug 20, 2020
Results first posted
Jan 11, 2021
Last update
Sep 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03502616
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 18, 2018
Start date
Jun 7, 2018
Primary completion
Dec 19, 2019
Completion
Aug 20, 2020
Results posted
Jan 11, 2021
Last update
Sep 17, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion